CancerInstituteReport_2023

Leading the Way in Cancer Prevention and Surveillance

While most may think of the Cancer Institute as a place where patients receive care for their cancer, it is also where we focus on preventing and catching cancer at its earliest, most curable stage. In 2023, the institute opened the High Risk Gastrointestinal (HiGl) Surveillance Clinic. This clinic is the most comprehensive, multidisciplinary resource in our community for people at an increased risk of developing gastrointestinal-related cancers in their lifetime. This clinic partners seamlessly with the University Genetics Oncology Clinic and supports patients identified at high risk. High-risk individuals include those at risk (due to family history or other reason) for any gastrointestinal cancer, including pancreatic, stomach or colorectal cancer, as well as colorectal polyposis due to a genetic condition like Lynch Syndrome. Many of these syndromes also require

risk management for other cancer types, such as breast or thyroid cancer, and this clinic strives to ensure that patients are up to date with appropriate screenings for these cancers as well. By leveraging the resources of our multidisciplinary team, we offer individualized high-risk surveillance based on each patient’s unique characteristics and genetic susceptibility. Our goal is early detection and prevention. The clinic offers each patient a personalized, multidisciplinary approach to patient care. Once established with the clinic, high-risk patients will see a combination of providers including physicians, genetic counselors, advanced practice providers, nurses and dieticians. The clinic provides patients with a centralized location for ongoing care that offers comprehensive, appropriate and effective management.

| Cancer Institute Annual Report 24

Made with FlippingBook interactive PDF creator